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Abstract
Background Whereas specific immunotherapy (SIT)
has already been shown to be cost-effective in the
treatment of allergic rhinitis compared with symp-
tomatic treatment, only a small number of investi-
gations have compared sublingual (SLIT) and subcu-
taneous (SCIT) immunotherapeutic approaches. This
analysis discusses the cost-effectiveness of SCIT com-
pared with SLIT and a symptomatic treatment modal-
ity. At the same time, particular attention is paid to
preparation-specific characteristics.
Methods The investigation is based on a previ-
ously published health economic model calculation.
A Markov model, with predefined disease stages and
a time period of 9 years, formed the basis of the
analysis. The data on specific SCIT (Allergovit®) and
SLIT (Oralair®) preparations required for the calcula-
tion were adjusted for the present analysis. Quality-
adjusted life years (QALYs) based on symptom scores
were calculated as the endpoint for effectiveness.
Furthermore, the total costs and cost effectiveness
of SCIT were determined. Model uncertainties were
estimated by means of additional sensitivity analyses.
Results With regard to effectiveness, both the SCIT
and SLIT preparations proved superior compared to
symptomatic treatment. Although more expensive,
SIT seem to be cost-effective. A direct comparison of
SCIT (Allergovit®) and SLIT (Oralair®) showed lower
total costs for SCIT treatment over the study period
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(SCIT 1159  versus SLIT 1322 ) and improved effec-
tiveness (SCIT 7.112 QALYs versus SLIT 7.060 QALYs).
Discussion SIT represents a cost-effective treatment
option for patients with allergic rhinitis compared
with symptomatic treatment. The comparison of
SCIT (Allergovit®) and SLIT (Oralair®) showed SCIT to
be predominant and cost-effective, due in particular
to somewhat greater patient compliance and lower
drug costs. It also became evident that, as far as pos-
sible, product-specific model variables are required
for an economic evaluation of SIT treatment.
Keywords Specific immunotherapy · Cost effective-









Allergic rhinitis (AR) is a common chronic disease as-
sociated with numerous symptoms that impair quality
of life [1]. In addition to the possibility of symptomatic
treatment, specific immunotherapy (SIT) has proven
to be a promising – and indeed the sole – causal treat-
ment option. Studies have already proved the effec-
tiveness and cost-effectiveness of SIT compared with
symptomatic treatment [2, 3]. What has not been suf-
ficiently investigated to date, however, is how an es-
timate of effectiveness, and in particular cost-effec-
tiveness, would look if sublingual (SLIT) and subcuta-
neous (SCIT) immunotherapy approaches were com-
pared with each other. A 2012 review was unable to
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provide a clear answer to this question at that time
[4]. The subject of cost and cost-effectiveness was
not addressed until 2015, when Verheggen et al. [5]
published an analysis of a five-grass tablet (Oralair®)
compared with a SCIT treatment mixture. This in-
vestigation was based on a health economic model
calculation over a 9-year time period. Such models
are widely used in health economics and are particu-
larly well suited to extrapolating existing findings over
a long time period and combining a range of different
data sources [6–8]. The authors concluded that, while
SLIT using Oralair® was associated with higher over-
all costs at 458 /patient over the study period, it also
proved to be superior in terms of effectiveness com-
pared with SCIT. On combining the benefit in quality-
adjusted life years (QALYs) and the cost difference be-
tween treatment approaches, the additional costs gen-
erally deemed cost-effective for Oralair® were 12,593 
per QALY gained. However, the results of model calcu-
lations such as this depend strongly on the underlying
data and assumptions. Bearing this in mind, a signifi-
cant limitation of this analysis lies, in our view, in the
selection of the comparative therapy. The compari-
son of a mix of SCIT treatment preparations, including
Depiquick®, Allergovit®, Pollinex®, and Purethal®, in
the study by Verheggen et al. [5] does not take the het-
erogeneity of the various individual preparations suf-
ficiently into consideration, given that the individual
drugs differ in terms of manufacturer-specific compo-
sition and clinical data. For this reason, the current
guideline on specific immunotherapy (SIT) focuses on
an individual consideration of each SIT preparation
[9].
The aim of the present analysis is to determine
the cost-effectiveness of SCIT using specific and ad-
equately documented grass-pollen immunotherapy
(Allergovit®) compared with SLIT using Oralair® or
symptomatic treatment in patients with grass pollen-
associated AR or rhinoconjunctivitis.
Definition of terms: what is a QALY?
The term QALY stands for “quality-adjusted life year.”
It is a parameter frequently used in international
health economic studies to reflect treatment effec-
tiveness from a patient view. The basic concept of the
QALY is an assessment of length of life in a state of
health in relation to the quality of life perceived by
the patient. According to the theoretical concept of
the QALY, quality of life is assigned a value between
1 (perfect health) and 0 (death). QALYs are arrived
at by multiplying the quality-of-life value with the
quantity-of-life value in this state of health. For ex-
ample, if patients live for 1 year with their quality
of life reduced by half, this year of life corresponds
to only 0.5 QALYs (quality of life 0.5 × 1 year). In
addition to permitting a consideration of the patient’s
perspective, QALYs also make it possible to compare
various treatments with each other, including those
for different indications.
Methods
The analysis was closely based on the model calcula-
tion published by Verheggen et al. [5], which was es-
sentially already published in an earlier publication by
Westerhout et al. 2012 [10]. In contrast to these earlier
calculations, the present analysis used specific model
variables that applied to the preparation Allergovit®.
Model assumptions
The Markovmodel underlying the calculation is based
on predefined disease stages which, once combined
with corresponding transition probabilities, make it
possible to predict the course of disease in a patient
cohort (Fig. 1). The treatment arms considered in-
cluded:
● SCIT with Allergovit®,
● SLIT with Oralair®,
● Symptomatic treatment alone.
The underlying Markov model has a 1-year cycle
length and a time horizon of 9 years. At the start of
the model calculation, patients had a mean age of
29 years and were affected by grass pollen-related AR
or rhinoconjunctivitis, but not allergic asthma (AA).
During the model duration, patients could develop
AA. For these patients a higher mortality and reduced
quality of life were assumed in the calculation. The
model also assumed that incident asthmatics during
the pollen season are affected by this disease over the
entire model period.
The possibility of additional symptomatic treat-
ment was allowed for in both SIT arms. SIT duration
was assumed to be 3 years. The transition probabili-
ties of the Markovmodel were adjusted accordingly to
the relevant treatment arm. For example, Verheggen
et al. [5] assumed a relative risk reduction of annual
AA incidence of 0.505 [11, 12], which was also adopted
in the present calculation. It was assumed that there
were no differences in risk reduction between SCIT
and SLIT. For those patients who discontinued SIT
before the end of the 3-year period, it was assumed
that no quality of life-enhancing results or risk-reduc-
ing effects on AA incidence would be seen following
SIT discontinuation. The percentage of patients that
discontinued SIT prematurely was determined on the
basis of the study results obtained by Kiel et al. [13]. It
was also assumed that patients did not re-initiate SIT
following discontinuation. The grass pollen season
lasts 4.5 months per year [14, 15].
Costs and use of resources
Costs for all treatment arms of the model were de-
termined from a health insurance perspective. Drug
costs for 3 years under Allergovit® were firstly ob-
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Fig. 1 Basic structureof theunderlyingMarkovmodel [5, 10] (all patients are at risk of death. This is not shown inorder to simplify
representation). AAallergic asthma,SCIT subcutaneous immunotherapy,SLIT sublingual immunotherapy
tained on the basis of the required prescription quan-
tities specified in the prescribing information [16].
The number of packs required for the entire treatment
period was then calculated according to the time pe-
riod covered by each pack. At 119–175 days, this
yielded a total number of packs of Allergovit® of one
per year. A similar approach was taken to establish
drug costs for Oralair®. According to the prescribing
information, treatment with Oralair® should be initi-
ated 4 months prior to, and continued throughout the
pollen season [17]. According to the information on
initiation and continued treatment, it was assumed
that two packs à 90 tablets, as well as two packs
à 31 tablets, were required per treatment year. The
number of required packs for both drugs was then
multiplied by the pharmacy retail price, including VAT
and deducting mandatory rebates [18]. On balance,
this yielded SIT drug costs of 1095  for Allergovit®
and 2669  for Oralair® for the entire 3-year treat-
ment period, with the costs distributed equally over
the 3 treatment years. For those patients who discon-
tinued SIT, drug costs were reduced by 50% for the
year in which treatment was discontinued.
The cost of additional symptomatic treatment was
calculated on the basis of costs previously estimated
by Verheggen et al. [5] for loratadine or budesonide.
The same applied to the costs of contact with medi-
cal specialists, SCIT injections, diagnostic costs, and
treatment costs upon onset of AA (Table 1). In ad-
dition to this, seven injections, as well as seven re-
lated contacts with medical specialists, were annually
assumed for patients under Allergovit® (preseasonal
treatment). Contact with a medical specialist was as-
sumed to take place on a quarterly basis among pa-
tients using Oralair®. As with Verheggen et al. [5],
1.9 contacts with medical specialists were assumed
for all SIT patients for the time following the 3-year
treatment period. Likewise, allergy diagnostic work-
up was performed in the first year in all SIT patients
prior to treatment initiation.
Effectiveness parameters
QALYs, which can be interpreted as length of life with
no impairments to quality of life, were the primary
outcome for therapeutic effectiveness. In a first step,
utility values reflecting impairment to quality of life
during the pollen season were determined based on
standardized symptom scores. Therefore the data of
a meta-analysis published in 2012 [19] were taken.
The symptom scores reported in that meta-analysis
adapted from a study by Corrigan et al. [20] were
used for the preparation Allergovit®, while the symp-
tom scores adapted from Didier et al. [21, 23], Wahn
et al. [22], and Cox et al. [24] were used for Oralair®.
Since the instruments used to determine symptoms
differed between these studies, a standardized mean
difference was firstly arrived on the basis of symptom
score information, and a standardized symptom score
then determined [25], as with the approach taken by
Verheggen et al. ([5]; Table 2). It was assumed that
symptoms were not present outside the pollen season.
QALYs were then calculated on the basis of utilities de-
termined in this way. As a further gauge of treatment
effectiveness, the number of new-onset cases of AA
was determined. All prognosed effects and costs were
discounted at a rate of 3%.
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Table 1 Model calculation inputdata
Model
assumptions
Mortality rate for allergic asthma p. a. [5] 0.07% Min-max variation in
sensitivity analyses
(%)
Background mortality rate p. a.[5] 0.05% ±30
Dropout rate for SCIT Allergovit®[13] Year 1 20% ±30
Year 2 49% ±30
Year 3 44% ±30
Dropout rate for SLIT Oralair®[13] Year 1 62% ±30
Year 2 53% ±30
Year 2 61% ±30
Asthma incidence p. a. [5] 0.46% ±30
Relative risk reduction in asthma incidence with SIT [5] 50.5% ±30




Costs for SCIT with Allergovit® over 3 years 1095.33  ±10
Costs for SLIT with Oralair® over 3 years 2668.86  ±10
Costs for loratadine per season [5] SIT 5.14  ±10
ST 7.54  ±10
Costs for budesonide per season [5] SIT 2.19  ±10
ST 3.83  ±10
Costs per contact with a medical specialist [5] 13.29  ±10
Costs per SCIT injection [5] 5.11  ±10
Diagnostic work-up [5] 20.61  ±10
Costs attributable to allergic asthma p. a. [5] 186.30  ±50
Number of annual physician contacts for SCIT with Allergovit® [16] 7 ±30
Number of injections p. a. for SCIT with Allergovit® [16] 7 ±30
Discount rate p. a. 3% ±30
SCIT subcutaneous immunotherapy, SLIT sublingual immunotherapy, ST standard treatment
















166.5 114.93 218 135.39 –0.410 3.0245 0.832
Oralair®
Didier et al. [21] 3.58 2.976 4.93 3.229 –0.431 – –
Wahn et al. [22] 3.25 2.86 4.51 2.93 –0.435 – –
Didier et al. [23] 2.67 3.63 4.03 3.71 –0.370 – –
Cox et al. [24] 3.21 4.54 4.16 4.51 –0.210 – –
– –0.343 (pooled) 3.26 0.819
Symptomatic treatment
Verheggen et al. [5], additional file: meta-analysis [25] 4.48 0.751
* Verheggen et al. [5], additional file: meta-analysis [25]
QALY quality-adjusted life year, SD standard deviation, SIT specific immunotherapy
Model calculation outcomes
Total costs per treatment group, QALYs, and the ex-
pected number of AA cases were considered as model
outcomes over the time period of 9 years. Incremen-
tal cost-effectiveness results are also reported (costs
per QALY gained) in the case of additional costs – but
greater therapeutic benefit – compared with the com-
parative treatments.
Sensitivity analysis
Sensitivity analyses are commonly used instruments
in health economics to estimate assumption-related
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Table 3 Per-patient costsover 9 yearsaccording to treatment type taking into account all patients in a treatment arm (including
those thatdroppedout fromSIT)
Type of cost Allergovit® Oralair® Symptomatic treatment
SIT 652  959  –
Symptomatic treatment 79  85  91 
Asthma costs 20  25  29 
Visits to a medical specialist 323  232  202 
Injections 64  – –
Allergy diagnostic work-up 21  21  –
Total costs per patient 1159  1322  322 
SIT specific immunotherapy
uncertainties in model results. Both probabilistic and
deterministic sensitivity analyses were performed in
the present investigation in order to estimate that in-
accuracy.
The particular feature of a probabilistic sensitivity
analysis is that a number of input data (from the value
ranges listed in Table 1) are drawn simultaneously and
at random. This procedure was repeated 1000 times
in the present analysis. Thus, by performing multi-
ple repetitions of the calculations, alternative analysis
results were obtained that graphically represent the
extent of uncertainty.
The deterministic sensitivity analysis, in contrast,
varied individual influencing factors in themodel con-
secutively with minimum and maximum values and
documented the main analysis result after each vari-
ation. In this way, it was possible to deduce the influ-




Over the 9-year time period, the total per-patient cost
of treatment with Allergovit® was 1159 , the aver-
age total per-patient cost with Oralair® 1322  (Ta-
ble 3). The majority of these costs are accounted
for by the drug costs associated with SIT treatment.
This becomes particularly apparent when one con-
siders the comparatively low total costs in the patient
group receiving symptomatic treatment alone. To-
tal costs per patient in this group were 322 . Based
on our assumptions on the SIT dropout rates used
in the model, only 228 of the 1000 patients initially
treated completed the entire 3-year treatment period
with Allergovit® and only 70 with Oralair®. The full SIT
drug costs used in the model applied only in these pa-
tients (over 3 years: 1095  for Allergovit®; 2669  for
Oralair®). On the other hand, if one takes all patients
into consideration (including those that dropped out),
one arrives at average SIT-specific drug costs of 652 
for Allergovit® and 959  for Oralair®. Treatment costs
for AA were comparatively modest due to the low AA
incidence of 0.46% per year.
Effectiveness
With regard to patient quality of life, both SIT groups
showed effects that were superior to symptomatic
treatment. This becomes evident from the num-
ber of QALYs determined. While 7036 QALYs over
the modeling period were determined for patients
receiving symptomatic treatment alone, treatment
with Allergovit® and Oralair® achieved 7112 and
7060 QALYs, respectively. This differencees are pri-
marily accounted for by the varying number of AA
cases occurring in the SIT treatment groups and the
differences in the percentage of patients that com-
pleted the entire 3-year SIT treatment period, and
thereby profited from the quality of life-enhancing
and AA incidence-lowering effects of SIT. While AA
occurred in 39 of 1000 patients receiving symptomatic
treatment only, the number of incident asthmatics is
lower at 31 cases (Allergovit®) and 36 cases (Oralair®).
Thus, the reduction in quality of life associated with
the presence of AA comes more relevant in the symp-
tomatic treatment group and results in fewer QALYs.
Cost-effectiveness
A comparison of Allergovit® with Oralair® revealed
SCIT to be economically superior, resulting in a sav-
ing of 163  (1159  vs. 1322 ). Since Allergovit® also
showed better effectiveness in terms of QALYs deter-
mined and the number of asthmatics, it predominates
over SLIT and is thus cost-effective.
A direct comparison of Allergovit® with symp-
tomatic treatment revealed additional costs of 837 
for SIT patients andbetter effects, both in terms of
QALYs gained and the number of new-onset AA cases.
However, QALY differences in relation to additional
costs also support the cost-effectiveness of Allergovit®
treatment. Thus, the costs per QALY gained are
11,000 , thereby putting them in the range consid-
ered as cost-effective (according to internationally
accepted threshold values of maximally 50,000  per
QALY gained).
Although Oralair® also showed better effects com-
pared with purely symptomatic treatment, the addi-
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tional costs here as well as the smaller effect difference
lead to increased cost per QALY gained of 41,405 .
Sensitivity analysis
Cost and effectiveness results were largely robust in
the sensitivity analysis. The replicated results demon-
strate that, compared with Oralair®, Allergovit® shows
the superior effectiveness of SCIT in virtually all cases,
both in terms of additional QALYs determined and
Allergovit®-related savings (Fig. 2). The robustness
of the results becomes even more apparent when
one compares Allergovit® with symptomatic treat-
ment. Here, the replicated results show only low
scatter around the mean value of QALY-differences.
The same applies to the cost differences (Fig. 3).
The deterministic sensitivity analysis revealed the
assumptions on SIT dropout rates, as well as the as-
sumed SIT drug costs, to be the model input variables
that give rise to the greatest degree of uncertainty in
terms of the cost results of the analysis. With regard
to QALYs determined in the treatment groups, these
were the assumptions set in the model calculation
about achievable symptom scores and pollen season
duration.
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Costs QALYs Cost-effectiveness evaluation
Dropout rate in the baseline calculation
SCIT 20 49 44 1159  7.112 SCIT dominates SLIT
SLIT 62 53 61 1322  7.060
Scenario 1
SCIT 62 53 61 838  7.065 SCIT still dominates SLIT
SLIT 1322  7.060
Scenario 2
SCIT 20 49 44 1159  7.122 SCIT still dominates SLIT
SLIT 1960  7.100
QALY quality-adjusted life year, SCIT subcutaneous immunotherapy, SLIT sublingual immunotherapy
Discussion
The results based on the present analysis suggest
that the treatment of patients with pollen-induced
rhinoconjunctivitis or AR using SCIT with Allergovit®
is both effective and cost-effective compared with
SLIT using Oralair® or purely symptomatic treatment.
This finding is based on an adaption of an existing
health economic model calculation previously pub-
lished by Verheggen et al. [5] and Westerhout et al.
[10]. These two studies drew conflicting conclusions;
however, they compared SLIT using Oralair® with
a SCIT treatment mix, which appears to be an unsuit-
able comparison given the heterogeneity of individual
SCIT preparations available on the market. Therefore,
for the purposes of this investigation, essentially only
those changes to the underlying model variables re-
quired to illustrate treatment with a specific SCIT
preparation (Allergovit®) were made.
However, a number of the differing input variables
used in this analysis require more detailed explana-
tion. For example, Verheggen et al. [5] andWesterhout
et al. [10] assumed an average pollen season duration
of 3 months in their model calculations. However,
since the current figures issued by the Meteorologi-
cal Institute at the Free University of Berlin suggest
that the grass pollen season appears to be effectively
longer, the present analysis differed in that it assumed
an average duration of 4.5 months [14].
Deviations from the model calculation published
by Verheggen et al. [5] also arose in terms of the per-
centage of patients that discontinued their SIT during
the treatment period. This appears to be particularly
relevant, since the deterministic sensitivity analysis
identified those dropout rates as model input vari-
ables that gave rise to a comparatively high degree of
uncertainty in the present analysis. The data used in
the study by Verheggen et al. [5] on treatment dis-
continuation before the end of the 3-year period were
based on an investigation by Sieber et al. 2011 [26],
whereas the present analysis used data from Kiel et al.
[13]. There are two main reasons for this: Firstly, the
data published by Sieber et al. [26] appear overly op-
timistic against the background of the recommenda-
tions for use of Oralair®, since one single prescribed
drug pack per year was considered sufficient to ful-
fill the compliance criterion. A further reason is the
detailed and indeed more realistic representation of
patient compliance in the publication by Kiel et al.
[13]. Whereas Sieber et al. [26] assumed 100% com-
pliance in the first year of therapy, Kiel et al. already
showed dropout figures for the corresponding phase
of their study. The validity of this assumption is also
supported by a further publication [27]. Nevertheless,
it should be noted at this point, that an alternative
calculation of the model on the basis of comparable
dropout rates for the SIT treatment arm does not fun-
damentally change the results of the present calcula-
tion. If one assumes the same dropout rates for SCIT
as for SLIT (and vice versa), the number of achiev-
able QALYs in the two treatment arms moves closer
together – albeit with SCIT still showing a slight su-
periority (Table 4). However, due to the differences in
the price of SIT preparations the cost saving benefit
of the SCIT will increase.
However, the costs of 3-year SIT are a further uncer-
tainty variable in the present model calculation. Here
again, the data used by Verheggen et al. [5] (Oralair®,
2100  versus SCIT treatment mix, 1450 ) differ from
those used in the present calculation (Oralair®, 2669 
versus Allergovit®, 1095 ). These differences can be
explained firstly by differing assumptions on the du-
ration of the pollen season, as well as by the use of
real prices in the current analysis, whereby it is as-
sumed that cost levels seen from the perspective of the
health insurance schemes are reflected more realisti-
cally. Nevertheless, it should be borne in mind when
considering these results that, since the SIT drug costs
account for a high proportion of total patient costs,
they strongly influence the cost results of the analy-
sis. Therefore, a future price change could result in
a reevaluation of costs and cost-effectiveness.
Besides SIT drug costs, other cost factors are also
included in the model calculation; for the purposes of
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better comparability, however, these costs are largely
aligned with the data already used by Verheggen et al.
[5]. Here again, however, limitations are evident, e. g.,
in terms of the costs attributable to the manifestation
of AA, which were put at 186  per season in the cal-
culation. This appears to be extremely low compared
with other investigations. For example, a 2003 study
concluded that the annual cost of treatment for adults
with AR increases from 1543  to 9287  as a result
of the additional presence of AA (costs attributable
to AA, 7744 ) [28]. Although, according to the au-
thors, 58% of these total costs are accounted for by
indirect costs (which are not taken into consideration
from the health insurance perspective in our analysis),
the remaining direct costs of 3252  are still signifi-
cantly higher compared with the present calculation.
This is particularly relevant when one considers the
low number of incident AA cases in the SCIT treat-
ment group. If higher costs had be set for all AA cases
that occurred, the difference in total costs would have
been more markedly in SCIT’s favor.
The non-consideration of indirect costs also has
other limitations, since, e. g., patients’ time costs are
omitted. It should be noted in this context that, unlike
SLIT, further indirect costs are incurred due to the ad-
ditional visits to medical professionals associated with
SCIT administration.
In terms of the effects of SIT on the relative risk
reduction for the manifestation of AA, the model cal-
culation assumes comparability between SCIT and
SLIT. Since no studies directly comparing SLIT and
SCIT in large patient cohorts have been published
to date, this assumption also represents a possible
limitation. A number of publications suggest the
stability of this assumption [29], while other stud-
ies comparing SCIT and SLIT demonstrate slightly
superior efficacy compared with placebo – accompa-
nied, however, by a greater potential for side effects
[30]. The current data seem to justify the assump-
tion that the treatment effects of SCIT, at least, are
more sustained. Whereas only study results spanning
a few years are available for SLIT [31], SCIT analy-
ses with Allergovit® demonstrate a sustained clinical
effect even at 12 years following the completion of
treatment [32].
Conclusion
Using preparation-specific variables in a health eco-
nomicmodel calculation, SCIT therapy with Allergovit®
was shown to be cost-effective in the treatment of
patients with AR. Although the two SIT treatments
exhibit essentially similar effectiveness in terms of AA
incidence, a cost-effectiveness benefit is seen for SCIT
compared with SLIT due, in particular, to the lower
dropout rates and lower drug costs. It also becomes
apparent that the results of health economic model
calculations can be strongly influenced by the under-
lying model assumptions, which in turn underlines
the need to use model variables that are as product-
specific as possible in order to perform an economic
assessment of SIT. It is precisely this type of product-
specific consideration that needs to be implemented
more rigorously in future medical comparisons and
economic evaluations of SIT.
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